Cover Image

Uptake of hepatitis C direct-acting antiviral treatment in China: a retrospective study from 2017 to 2021

Abstract Background Direct-acting antivirals (DAAs) for hepatitis C treatment in China became available since 2017. This study expects to generate evidence to inform decision-making in a nationwide scale-up of DAA treatment in China. Methods We described the number of standard DAA treatment at both...

Full description

Saved in:

Bibliographic Details
Main Authors:	Xinyu Du (Author), Jiarun Mi (Author), Hanchao Cheng (Author), Yuanyuan Song (Author), Yuchang Li (Author), Jing Sun (Author), Polin Chan (Author), Zhongdan Chen (Author), Simon Luo (Author)
Format:	Book
Published:	BMC, 2023-03-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Reported adverse events related to use of hepatitis C virus direct-acting antivirals with opioids: 2017-2021
by: Anthony Martinez, et al.
Published: (2023)

P20 Monitoring the uptake of hepatitis C: direct acting antiviral treatment in Australia
by: B. Hajarizadeh, et al.
Published: (2017)

Interventions to Improve Uptake of Direct-Acting Antivirals for Hepatitis C Virus in Priority Populations: A Systematic Review
by: David Ortiz-Paredes, et al.
Published: (2022)

Bioequivalent pharmacokinetics for generic and originator hepatitis C direct-acting antivirals
by: Andrew Hill, et al.
Published: (2018)

IP-10 Interferes With the Antiviral Response of Direct-Acting Antiviral Agents for Hepatitis C Virus Infection
by: Yadong Wang, et al.
Published: (2022)

Patients' preferences for treatment with the new direct acting antiviral therapies for chronic hepatitis C virus infection
by: MA Simón, et al.
Published: (2021)

Uptake and predictors of direct-acting antiviral treatment for hepatitis C among people receiving opioid agonist therapy in Sweden and Norway: a drug utilization study from 2014 to 2017
by: Christer F. Aas, et al.
Published: (2020)

Adoption of direct-acting antiviral medications for hepatitis C: a retrospective observational study
by: Leah L. Zullig, et al.
Published: (2019)

The effect of cognitive emotion regulation on direct-acting antivirals adherence in patients with hepatitis C
by: Adina Turcu-Stiolica, et al.
Published: (2024)

Strategies for treating and managing chronic hepatitis C in children in the direct-acting antiviral era
by: Suk-Jin Hong, et al.
Published: (2020)

Autoimmune hepatitis associated Hepatitis C virus infection treated with fi rst generation direct-acting antivirals
by: Juan Diego Castro Limo, et al.
Published: (2019)

Accessing hepatitis C direct acting antivirals among people living with hepatitis C: a qualitative study
by: Tony Antoniou, et al.
Published: (2023)

Virus infection and direct-acting antivirals in pregnancy
by: Xuan Huang, et al.
Published: (2022)

Continuum of hepatitis C care cascade in prison and following release in the direct-acting antivirals era
by: Sanam Hariri, et al.
Published: (2020)

Hepatitis C virus pharmacogenomics in Latin American populations: implications in the era of direct-acting antivirals
by: Trinks J, et al.
Published: (2017)

Retrospective Evaluation on Patient Screening and Counseling Service on Direct-acting Antivirals Against Hepatitis C
by: Bob Ka Him Wong, et al.
Published: (2020)

Effect of direct-acting antivirals on elastographic measures in patients with chronic hepatitis C virus infection
by: Mohamed M Sakr, et al.
Published: (2019)

Direct-acting antivirals for chronic Hepatitis C are effective and safe: an observational study in Londrina/PR
by: Hodnei Takashi Machado, et al.
Published: (2022)

Correction: Accessing hepatitis C direct acting antivirals among people living with hepatitis C: a qualitative study
by: Tony Antoniou, et al.
Published: (2023)

Results from a retrospective case finding and re-engagement exercise for people previously diagnosed with hepatitis C virus to increase uptake of directly acting antiviral treatment
by: David Etoori, et al.
Published: (2024)

Perceived physical health outcomes of direct-acting antiviral treatment for hepatitis C: a qualitative study
by: Stelliana Goutzamanis, et al.
Published: (2021)

Hepatitis C: sociodemographic and clinical profile of patients treated with direct-acting antivirals in a pharmaceutical office
by: Karem Aline Pegoraro, et al.
Published: (2023)

Predicting Treatment Failure for Initiators of Hepatitis C Virus Treatment in the era of Direct-Acting Antiviral Therapy
by: Nadia A. Nabulsi, et al.
Published: (2020)

Is direct-acting antiviral treatment beneficial or harmful for patients with hepatitis C virus-related hepatocellular carcinoma?
by: Hye Won Lee
Published: (2022)

Barriers to access to hepatitis C treatment with direct-acting antivirals in people who inject drugs in the community setting
by: Elena Yela, et al.
Published: (2024)

Price of a hepatitis C cure: Cost of production and current prices for direct-acting antivirals in 50 countries
by: Melissa J. Barber, et al.
Published: (2020)

Evaluation of the effect of direct-acting antiviral agents on melatonin level and lipid peroxidation in chronic hepatitis C patients
by: Nageh Ahmed El-Mahdy, et al.
Published: (2023)

High sustained virological response rates using imported generic direct acting antiviral treatment for hepatitis C
by: Andrew Hill, et al.
Published: (2017)

Impact of drug use policy on the appropriate use of direct acting antiviral agents for Hepatitis C in Saudi Arabia
by: Ahmed Saqer Alotaibi, et al.
Published: (2021)

Role of different direct-acting antiviral drugs on hepatitis C virus-associated mixed cryoglobulinemia in Egyptian patients
by: Tarek A Elshazly, et al.
Published: (2019)

The need for a European hepatitis C programme monitoring resistance to direct-acting antiviral agents in real life to eliminate hepatitis C
by: Stephanie Popping, et al.
Published: (2018)

Direct Acting Antiviral Drugs: Pharmacokinetics and Drug-Drug Interactions
by: Marina Barakat, et al.
Published: (2022)

Reversibility of some oxidative stress markers in chronic hepatitis C patients after receiving direct-acting antiviral agents
by: Pin-Nan Cheng, et al.
Published: (2023)

P55 Client acceptability and feasibility of expanded access to direct acting antiviral therapy for hepatitis at the Kirketon Road Centre
by: K.J. Chronister, et al.
Published: (2017)

The effectiveness and safety of direct-acting antivirals for hepatitis C virus treatment: A single-center experience in Saudi Arabia
by: Sumaiah J. Alarfaj, et al.
Published: (2022)

Efficacy and safety of direct-acting antivirals for treatment of hepatitis C infected kidney transplant recipients; a meta-analysis
by: Wisit Cheungpasitporn, et al.
Published: (2017)

The effect of direct acting antiviral agents on vascular endothelial function in Egyptian patients with chronic hepatitis C virus infection
by: Dalia A Freekh, et al.
Published: (2021)

High efficacy and safety of direct‐acting antivirals for the treatment of chronic hepatitis C: A cohort study conducted in Vietnam
by: Thong Duy Vo, et al.
Published: (2024)

Effect of direct-acting antivirals for hepatitis C virus-related hepatocellular carcinoma recurrence and death after curative treatment
by: Young-Hwan Ahn, et al.
Published: (2022)

Impact of direct acting antiviral agents on kidney function in hepatitis C virus infected patients with chronic kidney disease
by: Wedad Adel Mahmoud, et al.
Published: (2021)